✕ Sensationalism [4/10]: The headline uses 'weighs firing' which implies active deliberation but does not confirm intent, creating suspense without definitive claim. This is common in political reporting but borders on dramatization.

"Trump weighs firing Dr. Marty Makary as FDA chief"

✕ Framing by Emphasis [5/10]: The lead emphasizes 'simmering frustration' and potential firing, foregrounding conflict over policy or institutional context, which may skew reader perception toward drama.

"President Donald Trump is considering firing Dr. Marty Makary after simmering frustration with his performance as Food and Drug Administration commissioner"

✕ Loaded Language [6/10]: Terms like 'simmering frustration' and 'upheaval' carry emotional weight and imply instability, subtly shaping perception of Makary’s tenure as chaotic.

"Makary’s tenure as FDA chief has been marked by months of upheaval at the agency"

✕ Editorializing [5/10]: Describing Makary as 'seen as an ally' to RFK Jr. frames his appointment politically rather than professionally, potentially undermining neutrality.

"He was seen as an ally to Health Secretary Robert F. Kennedy Jr."

✕ Appeal to Emotion [4/10]: Mention of 'outrage' from Republicans over drug rejections introduces emotional reaction rather than focusing on clinical or regulatory rationale.

"The decision led to outrage, including from Republicans"

✓ Proper Attribution [8/10]: Key claims are attributed to named sources or outlets, such as 'a source familiar with the matter' and 'The Wall Street Journal reported', enhancing transparency.

"according to a source familiar with the matter"

✓ Proper Attribution [9/10]: Specific media attributions (e.g., Bloomberg News) are cited for claims about delayed safety reviews, supporting traceability.

"In December, Bloomberg News reported that Makary had told officials to delay releasing the review until after the midterm elections"

✕ Vague Attribution [5/10]: The article uses 'more than a year later, no review has been released' without specifying who is demanding it or why, weakening accountability.

"More than a year later, no review has been released"

✕ Omission [8/10]: The article omits that the FDA authorized flavored e-cigarettes on the same day, which contradicts the narrative of delay and may suggest recent action on vaping.

✕ Cherry-Picking [7/10]: Focuses on controversial drug rejections but does not mention any approvals or regulatory successes under Makary, creating an imbalanced picture.

✕ Selective Coverage [6/10]: Highlights political pressure on abortion pills and vaping but gives minimal context on scientific or regulatory challenges behind decisions.